Experimental Rheumatoid Arthritis Vaccine Shows Promising Results

Oct 21, 2021- by CMI| Category : Pharmaceutical1 min read
Experimental Rheumatoid Arthritis Vaccine Shows Promising Results

 

Researchers developed a protein based vaccine that prevents rheumatoid arthritis and enhances bone quality in animal models indicating long lasting benefits.

Scientists from the University of Toledo, U.S., found a new potential treatment for rheumatoid arthritis. The team developed an experimental protein-based vaccine that prevents the disease and improves bone quality in in animal models. Rheumatoid arthritis is a chronic inflammatory disease that affects joints including those in feet and hands. This excruciating disease that has no cure at present. According to the research published in the journal Proceedings of the National Academy of Sciences (PNAS) on August 24, 2021, the newly developed experimental vaccine treatment promises significant prevention of rheumatoid arthritis.

Rheumatoid arthritis is one of the most common autoimmune disease with high prevalence affecting 1% of the population all over the world. When immune system attacks healthy tissue particular the joints lining in wrists, hands, knee and ankles. Despite of its high prevalence, the disease has no cure. However, this research may have found a potential treatment. The research explored a protein known as 14-3-3 zeta as it is previously suspected to have a role in numerous autoimmune diseases. The team found that the lack of 14-3-3 zeta accelerated the disease progression in mice. More precisely, the scientists noticed as the animals were losing anti- 14-3-3 zeta antibodies, the arthritis appeared to be encouraged. Hence, the team created a new vaccine to fuel anti-14-3-3 zeta antibodies production. When tested the new protein based vaccine in some animal models, the progression of the disease was effectively prevented.

Moreover, the vaccine also drastically enhanced bone quality in the animals. The result of this experiment suggest long-lasting advantages of the protein-based vaccine following immunization. The safety and toxicity studies will be conducted soon after getting a partnership with pharmaceutical organizations. However, the team claims that the new discovery indicates potential treatment for rheumatoid arthritis.

Share this story

About the author

Nayan Ingle

is an Associate Content Writer with 3.5 years of experience specializing in research, content writing, SEO optimization, and market analysis, primarily within the consumer goods, packaging, semiconductor, and aerospace & defense domains. He has a proven track record of crafting insightful and engaging content that enhances digital visibility and provides valuable industry perspectives. Nayan’s expertise lies in producing content that is not only informative but also strategically optimized to reach target audiences effectively. His ability to blend market analysis with SEO strategies ensures that his work is both relevant and highly discoverable.

With an MBA in Systems (IT), Nayan brings a strong foundation in market strategies, business analytics, and research methodologies to his writing. This unique blend of skills allows him to offer in-depth analysis and thought leadership across a variety of content formats, including blogs, news articles, and editorial pieces. Passionate about delivering quality, Nayan is dedicated to providing readers with content that not only informs but also adds depth to ongoing industry conversations. His work reflects a commitment to excellence, and he continues to refine his approach as he keeps pace with evolving market trends.